Feasibility of magnetic liposomes as a targeting device for drugs.

Kojima, Hiroshi; Sato, J.; Yamada, Sunju; Kato, Yuriko

doi:10.1248/cpb.34.4253

Cited by 95 publications

(49 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Briefly, aliquots of 100 µL of liposomal solutions (PLDU) before and after purification, as well as M-PLDU, were mixed with 100 µL 5% Triton X-100 to destruct the liposome structure, followed by addition of 500 µL concentrated HCl to ionize the iron oxide; then 5 mL 1% hydroxylamine hydrochloride solution, 5 mL 0.1% O-phenanthroline solution, and 5 mL sodium acetate buffer (pH 4.6) were added. The mixture was diluted with deionized water to the final volume of 50 mL.…”

Section: Assay Of Encapsulated Iron Oxidementioning

confidence: 99%

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer

Deng¹,

Ke²,

He³

et al. 2012

IJN

View full text Add to dashboard Cite

Pancreatic cancer is a highly lethal disease with a 5-year survival rate less than 5% due to the lack of an early diagnosis method and effective therapy. To provide a novel early diagnostic method and targeted therapy for pancreatic cancer, a multifunctional nanoimmunoliposome with high loading of ultrasmall superparamagnetic iron oxides (USPIOs) and doxorubicin (DOX) was prepared by transient binding and reverse-phase evaporation method, and was conjugated with anti-mesothelin monoclonal antibody by post-insertion method to target anti-mesothelin-overexpressed pancreatic cancer cells. The in vitro and in vivo properties of this anti-mesothelin antibody-conjugated PEGlyated liposomal DOX and USPIOs (M-PLDU; and PEGlyated nanoimmunoliposome without antibody conjugation [PLDU]) were evaluated both in human pancreatic cancer cell line Panc-1 cell and in a pancreatic cancer xenograft animal model. Results showed that M-PLDUs were spherical and uniform with a diameter about ∼180 nm, with a zeta potential of about −28∼−30 mV, and had good efficacy encapsulating DOX and USPIOs. The in vitro study demonstrated that M-PLDUs possessed good magnetic resonance imaging (MRI) capability with a transverse relaxivity (r 2 ) of about 58.5 mM -1 ⋅ s -1 . Confocal microscopy showed more efficient uptake of M-PLDU in Panc-1 cells by antibodymediated targeting. Methyl thiazolyl tetrazolium assay results showed significant inhibitory effect of M-PLDU against Panc-1 cells (half-maximal inhibitory concentration, 1.95 µM). The in vivo imaging study showed that the tumor signal intensity (SI) dropped significantly about 4 hours after intravenous injection of M-PLDU. The decrease in tumor SI induced by M-PLDUs (∆SI = 145.98 ± 20.45) or PLDUs (∆SI = 75.69 ± 14.53) was much more significant than that by free USPIOs (∆SI = 42.78 ± 22.12; P , 0.01). The in vivo antitumor study demonstrated that compared with FD (free DOX) and PLDU, M-PLDU possessed higher inhibitory effect on tumor growth and the tissue distribution assay further proved that M-PLDUs could selectively accumulate in the tumor xenograft. These results indicated that M-PLDU not only well retained the inherent MRI capability of USPIOs, but significantly improved the targeting distribution of USPIOs and therapeutic agents in pancreatic tumor tissues. They may serve as a promising theranostic nanomedicine not only for early detection but also for MRI-monitored targeting therapy of human pancreatic cancer.

show abstract

Section: Assay Of Encapsulated Iron Oxidementioning

confidence: 99%

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer

Deng¹,

Ke²,

He³

et al. 2012

IJN

View full text Add to dashboard Cite

show abstract

“…Retention of magnetic carrier at target site can apparently delays reticuloendothelial clearance and neodisposition of the contained drug. Magnetic liposomes have been investigated for targeted drug carrying potentials (15)(16)(17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Lyophilized Paclitaxel Magnetoliposomes as a Potential Drug Delivery System for Breast Carcinoma via Parenteral Administration: In Vitro and in Vivo Studies

Zhang¹,

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The ferrofluid was composed of maghemite nanoparticles with diameter ranging approximately between 10 and 15 nm. The relative magnetic fluid concentration (25.2 mg mL -1 ) is given as the maghemite content determined by a colorimetric method (Kiwada et al 1986). All chemicals were used without any further purification.…”

Section: Methodsmentioning

confidence: 99%

Magnetically modified natural biogenic iron oxides for organic xenobiotics removal

Šafařı́k¹,

Filip²,

Horska³

et al. 2013

Current Opinion in Biotechnology

View full text Add to dashboard Cite

Biogenic iron oxides have been collected from a water stream and subsequently magnetically modified using water-based magnetic fluid. Both natural and magnetically modified materials have been characterized in detail using wavelength dispersive X-ray fluorescence spectrometry, X-ray powder diffraction, Mössbauer spectroscopy, electron microscopy and BET surface area measurements. The natural material is composed of 2-line ferrihydrite, forming hollow microtubules-sheaths of Leptothrix ochracea, and detrital components. As a result of the ferrofluid modification, maghemite nanoparticles were identified on the surface of the treated material. The active surface area of the bulk, magnetically-modified sample was 148 m 2 g -1 .The magnetically modified material was tested as inexpensive magnetically responsive adsorbent for the removal of selected organic xenobiotics, namely organic dyes, from aqueous solutions. The observed maximum adsorption capacities ranged between 34.3 and 97.8 mg of dye per 1 g of adsorbent.

show abstract

Feasibility of magnetic liposomes as a targeting device for drugs.

Cited by 95 publications

References 2 publications

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer

Lyophilized Paclitaxel Magnetoliposomes as a Potential Drug Delivery System for Breast Carcinoma via Parenteral Administration: In Vitro and in Vivo Studies

Magnetically modified natural biogenic iron oxides for organic xenobiotics removal

Contact Info

Product

Resources

About